Mission Therapeutics pairs brain-penetrant mitochondria drug with NeuraLight’s eye-tracking biomarkers in a multi-country Parkinson’s trial.
There’s a cleanup job happening inside your cells right now, and most of the time you’d never notice it. Mitochondria wear out. When they do, a process called mitophagy is supposed to clear them away before they cause trouble. In Parkinson’s disease, that clearing job appears to stall – damaged mitochondria pile up, dopamine-producing neurons start dying off and the tremors and stiffness that define the disease eventually follow.
Mission Therapeutics, based in Cambridge, UK, has built a drug around fixing exactly that stall. The company announced a partnership with NeuraLight, a brain-measurement startup with a foothold in New York and Tel Aviv, to help figure out with real precision whether the drug is actually doing what it’s supposed to. The tool they’re using to check: a camera, pointed at a patient’s eyes [1].
Blocking the brake, not building a new engine
The drug is called MTX325. It targets an enzyme, USP30, that normally puts a brake on mitophagy, so blocking USP30 should, in theory, let the cleanup process resume. Mission didn’t invent the idea from scratch; preclinical work published in Nature showed that blocking USP30 protected against the specific kind of dopamine-neuron loss seen in Parkinson’s. That’s the mechanism the company is now trying to translate into an actual treatment.
It’s further along than a lot of early neuroscience bets. Phase Ia trials in healthy volunteers, backed by spinal fluid sampling and brain imaging, already confirmed MTX325 reaches the brain, not something you can assume for a molecule this targeted. It’s now moving into a Phase Ib trial in Parkinson’s patients across sites in the UK, Europe and Australia.
A more objective way to watch the brain work
Here’s the problem NeuraLight is being brought in to solve. Parkinson’s is usually tracked with clinical rating scales: a doctor watches someone walk, tap their fingers, hold a pose and scores it. It’s a system that works reasonably well but leans heavily on one person’s judgment call, and it can miss small changes early on. NeuraLight’s platform swaps that out for something measured – using AI and computer vision to track eye movements, which reflect activity across many of the same neural circuits Parkinson’s disrupts.
“Mission is excited to be part of this pioneering approach to assessing oculometric changes, and we are delighted to be working with the NeuraLight team,” said Dr Sarah J Fritchley, Mission’s chief development officer.
NeuraLight co-founder and chief executive Edmund Ben-Ami was more specific about what the measurement actually has to do.
“Mission engineered MTX325 to protect neurons by restoring a fundamental process in the brain, and our platform is built to measure whether that protection shows up as preserved brain function,” he said. “That requires measurement sensitive enough to catch a signal in a small early-phase trial, and robust enough to hold up across a large, multisite one.”
NeuraLight’s platform isn’t a one-drug tool, either; the company says it’s applying the same eye-movement measurement approach across Alzheimer’s, ALS and Huntington’s disease, conditions where subtle functional change is notoriously hard to pin down with a stopwatch and a checklist.
Where aging science actually meets Parkinson’s
Mitochondrial decline shows up again and again on lists of what drives biological aging, not just in Parkinson’s, but in heart failure, muscle loss, general frailty. A drug aimed squarely at restoring the brain’s own mitochondrial cleanup, paired with a measurement tool precise enough to prove whether that restoration means anything a patient can feel, sits right at the overlap of neurodegeneration research and aging biology more broadly. If the mechanism holds up in Parkinson’s patients, there’s little reason to think its relevance stops there.
